A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an efficacious dose of QAT370 compared to open-label tiotropium bromide following once daily dosing for 7 days in COPD [chronic obstructive pulmonary disease] patients
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2010
At a glance
- Drugs QAT 370; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 20 Jan 2008 Status changed from recruiting to completed.
- 02 Oct 2007 New trial record.